IRIS
CICCARELLI, LEONARDINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.288
AS - Asia 2.699
EU - Europa 2.000
SA - Sud America 284
AF - Africa 64
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 4
Totale 8.343
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.215
CN - Cina 1.525
SG - Singapore 559
IE - Irlanda 516
UA - Ucraina 369
DE - Germania 273
FI - Finlandia 246
HK - Hong Kong 225
BR - Brasile 207
RU - Federazione Russa 184
VN - Vietnam 163
FR - Francia 104
SE - Svezia 102
IT - Italia 83
IN - India 63
GB - Regno Unito 59
CA - Canada 42
ZA - Sudafrica 33
IQ - Iraq 24
AR - Argentina 23
BD - Bangladesh 22
NL - Olanda 15
MX - Messico 14
TR - Turchia 14
EC - Ecuador 13
JO - Giordania 11
PL - Polonia 11
CL - Cile 10
PK - Pakistan 10
UZ - Uzbekistan 10
VE - Venezuela 10
JP - Giappone 9
SA - Arabia Saudita 9
LT - Lituania 8
MA - Marocco 8
PH - Filippine 8
BO - Bolivia 7
ES - Italia 7
CO - Colombia 6
ID - Indonesia 6
IR - Iran 6
MY - Malesia 6
EG - Egitto 5
NP - Nepal 5
AL - Albania 4
EU - Europa 4
KE - Kenya 4
NI - Nicaragua 4
PY - Paraguay 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
BE - Belgio 3
CR - Costa Rica 3
GE - Georgia 3
NZ - Nuova Zelanda 3
PA - Panama 3
AT - Austria 2
AZ - Azerbaigian 2
BB - Barbados 2
CY - Cipro 2
DZ - Algeria 2
GR - Grecia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LU - Lussemburgo 2
OM - Oman 2
PE - Perù 2
PT - Portogallo 2
UG - Uganda 2
AD - Andorra 1
AO - Angola 1
AU - Australia 1
BN - Brunei Darussalam 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GA - Gabon 1
HN - Honduras 1
HR - Croazia 1
IL - Israele 1
JM - Giamaica 1
KH - Cambogia 1
KR - Corea 1
LA - Repubblica Popolare Democratica del Laos 1
LC - Santa Lucia 1
LK - Sri Lanka 1
LS - Lesotho 1
MD - Moldavia 1
NG - Nigeria 1
RO - Romania 1
SI - Slovenia 1
SN - Senegal 1
SR - Suriname 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 8.343
Salva come PNG Salva come JPEG
Città #
Dublin 516
Jacksonville 480
San Jose 415
Chandler 396
Nanjing 350
Singapore 263
Ashburn 242
Beijing 229
Hong Kong 218
Dallas 212
Nanchang 156
Boardman 149
Shenyang 121
Princeton 107
Jiaxing 103
Wilmington 103
Changsha 100
Lawrence 95
Hebei 92
Medford 81
Lauterbourg 80
Tianjin 66
Los Angeles 62
Hangzhou 52
Ho Chi Minh City 44
Munich 39
Hanoi 38
Helsinki 38
New York 38
Buffalo 37
Redondo Beach 35
Johannesburg 31
Toronto 26
Seattle 25
Shanghai 25
Moscow 24
Norwalk 22
Santa Clara 20
São Paulo 20
Council Bluffs 18
Frankfurt am Main 18
Turku 18
Orem 16
Des Moines 14
Woodbridge 13
Fairfield 12
Milan 12
San Francisco 12
Jinan 11
Pune 11
Amman 10
Ann Arbor 10
Atlanta 10
Baghdad 10
Haiphong 9
Quito 9
Kunming 8
London 8
Montreal 8
Poplar 8
Tokyo 8
Warsaw 8
Chennai 7
Dearborn 7
Tashkent 7
Belo Horizonte 6
Da Nang 6
Eindhoven 6
Lanzhou 6
Rio de Janeiro 6
Rome 6
Verona 6
Brooklyn 5
Guangzhou 5
New Delhi 5
Ningbo 5
Taizhou 5
Washington 5
Amsterdam 4
Biên Hòa 4
Caracas 4
Casablanca 4
Halifax 4
Istanbul 4
Jeddah 4
Managua 4
Manchester 4
Nairobi 4
Orange 4
Porto Alegre 4
Stockholm 4
Tehran 4
Zhengzhou 4
Boston 3
Brasília 3
Brussels 3
Bắc Giang 3
Bắc Ninh 3
Bến Tre 3
Campinas 3
Totale 5.585
Salva come PNG Salva come JPEG
Nome #
Confronto tra nateglinide più metformina rispetto a glibenclamide più metformina sul metabolismo glucidico nei pazienti diabetici di tipo 2: studio ad 1 anno 132
Association between low-molecular weight apolipoprotein(a) isoforms and obesity in Italian women 129
Azione della moxonidina sul metabolismo glucidico e lipidico negli ipertesi con sindrome metabolica 129
Confronto tra pioglitazone e rosiglitazone sul metabolismo glucidico e lipidico nei soggetti diabetici di tipo 2 in terapia con metformina 127
Atorvastatin-amlodipine combination and fibrinolytic balance in hypertensive hypercholesterolemic insulin-resistent patients 126
Comparison between diet, orlistat and fluvastatin in obese patients with mild hypertension and hypercholesterolemia 125
Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial 123
Effetti di pioglitazone e rosiglitazone nei pazienti con diabete di tipo 2 e sindrome metabolica trattati con metformina 122
Confronto tra dieta, orlistat e fluvastatina in soggetti obesi, con ipertensione arteriosa lieve e ipercolesterolemia 122
Effetti metabolici di telmisartan e irbesartan nei pazienti diabetici di tipo 2 con sindrome metabolica trattati con rosiglitazone 122
Actions of glimepiride plus metformin compared to rosiglitazone plus metformin on glucose metabolism, fibrinolytic, and coagulation measurements in Type 2 diabetic patients. 122
Comparison between orlistat and sibutramine in obese patients with mild hypertension 120
Comparison between exenatide and glimepiride on metabolic control and on insulin resistance in type 2 diabetic patients with metformin therapy 110
Comparison between glimepiride plus pioglitazone vs. glimepiride plus rosiglitazone on glucose metabolism and on lipid, lipoprotein and apolipoprotein fractions in type 2 diabetic patients 110
Azione della moxonidina sul metabolismo glucidico e lipidico negli ipertesi con sindrome metabolica 107
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients 106
Comparison between fosinopril and eprosartan on lipid profile and Lp(a) in normotensive, type 2 diabetic subjects, with microalbuminuria 106
Metalloproteasi-2, metalloproteasi-9 ed inibitore tissutale delle metalloproteasi-1 in pazienti ipertesi 106
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome 106
Doxazosin improves blood pressure and metabolic parameters in impaired glucose tolerance patients in therapy with acarbose 106
Changes during glimepiride plus rosiglitazone vs glibenclamide plus rosiglitazone treatment on glucose metabolism and lipoprotein (a) in Type 2 diabetic patients. 105
Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic insulin-resistant patients 105
High Lp(a) levels and atherogenic isoforms in patients with acute coronary sindrome 103
Effects of rosiglitazone alone and in association with simvastatin on lipid and lipoprotein parameters in patients with metabolic syndrome 103
Effetti dell'associazione tra pioglitazone e sibutramina sul metabolismo glucidico e lipidico nei soggetti obesi diabetici di tipo 2 103
Le metalloprotesi -2 e -9 e i loro inibitori tissutali -1 e -2 nei soggetti sani e nei soggetti con diabete di tipo 2 101
MMP-2, -9 and TIMP-1 in patients with hypertension before and after doxazosin therapy 101
Efficacy of fluvastatin together with fenofibrate in hypercholesterolemic type 2 diabetic subjects compared to monotherapy. 99
Effetti metabolici di telmisartan e irbesartan nei apzienti diabetici di tipo 2 con sindrome metabolica trattati con rosiglitazone 98
Comparison between repaglinide plus metformin vs glimepiride plus metformin on glucose metabolism, fibrinolytic, and coagulation measurements in Type 2 diabetic patients: a 1 year 95
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin on diabetic dyslipidemia 94
Efficacia e sicurezza di pioglitazone o rosiglitazone in combinazione con metformina in pazienti con diabete di tipo 2 e sindrome metabolica 92
Matrix metalloproteinases and tissue inhibitor metalloproteinases in hypertensive patients 91
La doxazosina migliora i parametri pressori e l'assetto metabolico nei soggetti intolleranti al glucosio in terapia con acarbose 90
Fosinopril vs eprosartan in normotensive, Type 2 diabetic patients, with microalbuminuria 89
Comparison between glimepiride plus metformin vs rosiglitazone plus metformin on glucose metabolism and on blood pressure in Type 2 diabetic patients 89
Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients 88
Efficacia di fluvastatina e fenofibrato in prevenzione secondaria rispetto alla monoterapia: studio ad 1 anno in pazienti diabetici di tipo 2, ipercolesterolemici 87
La terapia con rosiglitazone migliora i parametri di insulino-resisitenza nei pazienti diabetici in sovrappeso ed obesi intolleranti alla metformina 86
Matrix metalloproteinase-2,-9 and tissue inhibitor metalloproteinase-1,-2 in healthy and type 2 diabetic subjects 86
Glycemic and extraglycemic effects of glimepiride plus pioglitazone vs glimepiride plus rosiglitazone therapy in Type 2 diabetic patients 85
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin on diabetic dyslipidemia 84
Metabolic and insulin resistance-related indices during pioglitazone and vildagliptin association versus glimepiride and vildagliptin association in type 2 diabetic patients 84
Le metalloproteasi-2, -9 in differenti gruppi con e senza diabete 83
Comparison between repaglinide plus metformin vs glimepiride plus metformin on glucose metabolism and lipoprotein (a) in type 2 diabetic patients: A 1-year study 83
Pioglitazone or rosiglitazone added onto metformin in type 2 diabetes with metabolic syndrome: effects on conventional and non-conventional cardiovascular risk factors 83
Effects of telmisartan compared to nifedipine in hypertensive, type 2 diabetic patients on glucose metabolism and lipid profile: a 1-year study 82
Efficacia e sicurezza del pioglitazone o rosiglitazone in combinazione con metformina su pazienti diabetici dislipidemici 82
Matrix metalloproteinase 2 and 9 values in various groups with or without diabetes 82
Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin 81
Matrix metalloproteinase 2 and 9 levels in diabetic and nondiabetic patients during and after acute coronary syndrome 81
Matrix metalloproteinase-2, -9 and tissue inhibitor metalloproteinase-1, -2 in healthy and type 2 diabetic subjects 81
Moxonidine action on glucose and lipid metabolism in hypertensive patients with metabolic syndrome 81
Matrix metalloproteinase 2 and 9 evaluation in different patient groups with or without diabetes 81
Comparison between Glimepiride Plus Rosiglitazone on Glucose Metabolism and on Lipid, Lipoprotein and Apolipoprotein Parameters in Type 2 Diabetic Patients 81
La doxazosina migliora i parametri pressori e l'assetto metabolico nei soggetti intolleranti al glucosio in terapia con acarbose 81
Effects of exenatide compared to glibenclamide on glycemic control and on insulin resistance in type 2 diabetic patients with metformin therapy 80
Matrix metalloproteinases and tissue inhibitor metalloproteinases in hypertensive patients before and after antihypertensive therapy 80
Matrix metalloproteinase-2, -9 and tissue inhibitor Metalloproteinase-1 in patients with hypertension 79
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone 79
Effetti metabolici di telmisartan e irbesartan nei pazienti diabetici di tipo 2 con sindrome metabolica trattati con rosiglitazone 79
Matrix metalloproteinase 2 and 9 values in various groups with or without diabetes 79
Matrix metalloproteinase-2, -9, and tissue inhibitor metalloproteinase-1 in patients with hypertension before and after doxazosin therapy 79
Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin 78
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone: a double-blind, randomised clinical trial 78
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome 78
Terapia con telmisartan e irbesartan nei pazienti con diabete di tipo 2 trattati con rosiglitazone: effetti sull'insulino-resistenza, leptina e TNF-alfa 77
La doxazosina migliora i parametri pressori e l'assetto metabolico nei soggetti intolleranti al glucosio in terapia con acarbose 77
Valutazione endocrino-metabolica di una popolazione di pazienti obesi e confronto con soggetti normopeso 77
La sibutramina non modifica i parametri emodinamici bnegli obesi, diabetici di tipo 2 75
Efficacy of fluvastatin together with fenofibrate in secondary prevention compared to monotherapy in hypercholesterolemic, type 2 diabetic subjects: A 1-year study 74
Prevalenza di elevati livelli di Lp(a) e di isoforme aterogene in un gruppo di pazienti del Nord Italia con sindrome coronarica acuta 74
Pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome: effects on conventional and non-conventional cardiovascular risk factors 74
Valutazione delle metalloproteasi 2 e 9 in pazienti con o senza diabete durante sindrome coronarica acuta e dopo evento acuto 74
Pioglitazone and sitagliptin compared to pioglitazone and metfomin therapy on glycaemic control and on insulin resistance in type 2 diabetic patients 72
Matrix metalloproteinase-2,-9 and tissue inhibitor metalloproteinase-1,-2 in patients with acute coronary syndrome with or without diabetes during and after acute event 72
Fenofibrate and fluvastatin compared to monotherapy in hypercholesterolemic diabetic patients with coronary heart disease: a 1 year study 72
Stress ossidativo e rischio vascolare. Quale ruolo per gli antiossidanti? 71
Pioglitazone o rosiglitazone in associazione con metformina nei pazienti con diabete mellito di tipo 2 e sindrome metabolica: effetto sui fattori di rischio cardiovascolare convenzionali e non convenzionali 70
Il sistema di monitoraggio continuo della glicemia nei soggetti sani: risultato di uno studio pilota 70
Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: A randomized placebo-controlled trial 70
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin on diabetic dyslipidemia 70
Le metalloproteasi-2, -9 nei pazienti diabetici con sindrome coronarica prima e dopo l'evento acuto 69
Effetti di exenatide in combinazione con metformina sulla funzione beta-cellulare in pazienti affetti da diabete mellito di tipo 2 69
Glycemic control and cardiovascular risk profile in patients with type 2 diabetes treated with repaglinide or metformin 68
Pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome: effects on markers of cardiovascular disease 68
The improvement of Insulin-Resistance with Rosiglitazone Plus Metformin Compared to Glimepiride Plus Metformin Lowers Blood Pressure Values in Type 2 Diabetic Patients 67
Effects of Telmisartan Compared to Nifedipine in Hypertensive, Type 2 Diabetic Patients on Glucose Metabolism and Lipid Profile: A 1-Year Study 66
Valutazione delle metalloproteasi 2 e 9 in differenti gruppi di pazienti con o senza diabete 65
Lipid and lipoprotein effects of rosiglitazone alone and in association with simvastatin in patients with metabolic syndrome 63
Effetti dell'associazione tra pioglitazone e sibutramina sul metabolsimo glucidico e lipidico nei soggettiobesi diabetici di tipo 2 62
Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes 62
Effetti metabolici di telmisartan e irbesartan nei pazienti diabetici di tipo 2 con sindrome metabolica trattati con rosiglitazone 60
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone 59
Effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin 51
Totale 8.363
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.646
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.646
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202117 0 0 0 0 0 0 0 0 0 0 0 17
2021/2022350 0 0 18 1 1 0 4 23 12 2 69 220
2022/20231.329 121 105 2 67 129 139 0 86 602 7 47 24
2023/2024410 30 103 19 32 32 103 5 43 3 12 12 16
2024/20251.068 8 107 46 37 10 31 61 77 262 6 115 308
2025/20262.550 261 175 261 217 267 118 559 112 238 217 86 39
Totale 8.363